Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Chronic lymphocytic leukemia (CLL) affects lymphocytes. Lymphocytes are a type of white blood cell (WBC). CLL specifically affects B lymphocytes, which are also called B cells. Normal B cells ...

Chronic lymphocytic leukemia (CLL) has a relatively high survival ... Bone marrow is a soft, spongy substance within bones that produces blood cells. CLL is the result of various genetic mutations ...

such as chimeric antigen receptor–NK cell treatment. Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have ...

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...

Possible signs of leukemia include fevers, fatigue, bleeding, and bruising.There are many types of leukemia, and they may ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia ... it from the very different disease of chronic lymphocytic leukemia, which has a potential time course ...

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... that something happens to change the genetic code inside your cells that make white blood cells. Normally, these cells help your ...

chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) reveal that a changed score of −11/+11 for symptom burden, −16/+16 for physical condition/fatigue and −16/+13 for ...

Among the efficacy evaluable patients, 42% achieved complete remission within 3 months. The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the ...